Sheaff Brock Investment Advisors LLC Increases Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Sheaff Brock Investment Advisors LLC lifted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 13.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,238 shares of the company’s stock after acquiring an additional 268 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Neurocrine Biosciences were worth $258,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NBIX. Vanguard Group Inc. grew its stake in shares of Neurocrine Biosciences by 2.3% during the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock valued at $1,369,673,000 after buying an additional 220,598 shares during the last quarter. Renaissance Technologies LLC increased its stake in Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after purchasing an additional 216,500 shares during the period. AQR Capital Management LLC lifted its position in shares of Neurocrine Biosciences by 23.0% during the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after purchasing an additional 228,444 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Neurocrine Biosciences by 1.4% during the second quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock valued at $128,639,000 after purchasing an additional 13,069 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Neurocrine Biosciences by 40.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock worth $97,828,000 after purchasing an additional 203,934 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on NBIX. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. Guggenheim increased their price objective on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Royal Bank of Canada reduced their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Finally, Oppenheimer raised their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Trading Down 4.4 %

Shares of NBIX stock opened at $117.44 on Friday. Neurocrine Biosciences, Inc. has a 12-month low of $107.84 and a 12-month high of $157.98. The business’s fifty day simple moving average is $118.50 and its 200-day simple moving average is $132.66. The company has a market cap of $11.89 billion, a PE ratio of 31.49 and a beta of 0.35.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.